20th Mar 2019 13:38
LONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC has received a new patent for its Modi-1 drug candidate in the US, it said on Wednesday.
The patent, granted by the US Patent Office, follows similar patents granted in Europe, South Africa, Australia and, Scancell said, soon in China.
Cancer treatment Modi-1 is the first clinical candidate from Scancell's Moditope immunotherapy platform.
Scancell also has been granted a European patent for FG88, an antibody which is directed at tumour associated glycans.
Chief Executive Cliff Holloway said: "We are pleased to have been granted these two important patents for our immunotherapy platforms in the US and Europe. This Moditope patent provides protection for Modi-1 in the US and further endorses the novelty of Scancell's work in identifying a new class of cancer vaccine.
"Through the continued expansion of our intellectual property portfolio in the US and Europe, we believe we are well positioned to advance our pipeline of novel immunotherapies."
Shares were 5.4% higher on Wednesday at 5.90 pence each.
Related Shares:
Scancell Holdings